Although the COVID-19 pandemic will have a negative impact on procedure volumes and market growth in 2020, the global market for structural heart closure devices will grow rapidly in most countries covered through 2029, driven by strong clinical data, the availability of reimbursement, a growing body of trained physicians, and the uptake of premium priced technologies, especially in the PFO and LAA closure device spaces.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the global structural heart closure device market across a 10-year period.
The global structural heart closure device market will be impacted by the COVID-19 pandemic in the early years of the forecast.
What guidance or recommendations have been issued for structural heart closure procedures in the face of infection containment and self-isolation measures?
How will the pandemic impact clinical trials and product launches?
The global market for structural heart closure devices will grow rapidly throughout the forecast period.
Which segment contributed the most to global revenues in 2019?
Which segments are contributing the most to overall global growth?
What are the different growth trends by region? How has the reimbursement landscape changed for structural heart closure procedures in different geographies?
Results from the NHS Clinical Commissioning Policy evaluation program will have a strong impact on procedure volumes in the UK.
Which procedures were affected by the Clinical Commissioning Policy in the UK?
What is the impact of the evaluation program on the UK structural heart closure device market?
Clinical data and treatment guidelines for procedures like LAA and PFO closures will drive the use of percutaneous closure devices.
What are the most recent trials and studies that have taken place in the dialysis access treatment device space?
How will clinical trial results impact this market?
The LAA closure device segment represents a significant market opportunity for manufacturers in the structural heart closure device space.
What are the differences between epicardial and endocardial LAA closure devices and how will these differences affect trends going forward?
How will the global endocardial LAA market be affected by the PMDA approval of Boston Scientific's WATCHMAN device in 2019? How can other companies challenge Boston Scientific in this high-growth market?
The global market for PFO closure devices has experienced turbulence in the past but is positioned for growth given recent positive clinical data and updated reimbursement policies.
What new clinical evidence challenges the historically troubled body of evidence for PFO closure?
How is the patient population for PFO closure defined and how is it different between geographies?
Which country will be impacted by the changes in the reimbursement policies for PFO closure procedure and how will this affect the procedure volumes going forward?
- Structural Heart Closure Devices - Market Insights - Global
Author(s): Sangeetha Iyer, Pharm.D
Sangeetha Iyer is an analyst within the Cardiovascular Medtech Insights team at Decision Resource Group, specializing in structural heart closure and vascular access device markerts across the Asia Pacific region, as well as medical device pricing and regulations in China and Japan. Sangeetha has represnted India at the European Society of Cardiology confrerence in Greece(2016) and Sweden(2017), where her research poster was awarded the top prize. Sangeetha holds a Doctor of Pharmacy degree from the Manipal Academy of Higher Education. Follow Sangeetha on twitter: @Slyer_DRG